- Home
- PBPB vs NLSP Comparison
PBPB vs NLSP Comparison
Compare PBPB & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- NLSP
- Stock Information
- Founded
- PBPB 1977
- NLSP 2015
- Country
- PBPB United States
- NLSP Switzerland
- Employees
- PBPB N/A
- NLSP N/A
- Industry
- PBPB Restaurants
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- PBPB Consumer Discretionary
- NLSP Health Care
- Exchange
- PBPB Nasdaq
- NLSP Nasdaq
- Market Cap
- PBPB 253.7M
- NLSP 243.8M
- IPO Year
- PBPB 2013
- NLSP 2021
- Fundamental
- Price
- PBPB $9.97
- NLSP $3.37
- Analyst Decision
- PBPB Strong Buy
- NLSP
- Analyst Count
- PBPB 3
- NLSP 0
- Target Price
- PBPB $15.67
- NLSP N/A
- AVG Volume (30 Days)
- PBPB 179.6K
- NLSP 626.4K
- Earning Date
- PBPB 11-07-2024
- NLSP 11-29-2024
- Dividend Yield
- PBPB N/A
- NLSP N/A
- EPS Growth
- PBPB 641.95
- NLSP N/A
- EPS
- PBPB 1.25
- NLSP N/A
- Revenue
- PBPB $471,719,000.00
- NLSP N/A
- Revenue This Year
- PBPB N/A
- NLSP N/A
- Revenue Next Year
- PBPB $3.41
- NLSP N/A
- P/E Ratio
- PBPB $7.96
- NLSP N/A
- Revenue Growth
- PBPB N/A
- NLSP N/A
- 52 Week Low
- PBPB $6.28
- NLSP $3.00
- 52 Week High
- PBPB $14.36
- NLSP $29.08
- Technical
- Relative Strength Index (RSI)
- PBPB 63.38
- NLSP 37.40
- Support Level
- PBPB $9.53
- NLSP $3.01
- Resistance Level
- PBPB $10.94
- NLSP $3.55
- Average True Range (ATR)
- PBPB 0.50
- NLSP 0.43
- MACD
- PBPB 0.06
- NLSP -0.01
- Stochastic Oscillator
- PBPB 72.52
- NLSP 20.98
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.